Development of a T cell specific multiple sclerosis drug

Medicine & Life Sciences

1. Alleles 12%
2. Animal Models 25%
3. Animals 8%
4. Antibody Formation 8%
5. Antigens 11%
6. Autoantigens 19%
7. Autoimmune Experimental Encephalomyelitis 96%
8. Autoimmunity 16%
9. Biological Assay 10%
10. Calcium 6%
11. Clinical Studies 20%
12. Clinical Trials 11%
13. Clinical Trials, Phase I 12%
14. Cytokines 6%
15. Dichlororibofuranosylbenzimidazole 25%
16. Gadolinium 10%
17. Genes 7%
18. Guidelines 6%
19. HLA-DR2 Antigen 15%
20. Hybridomas 11%
21. Injections 11%
22. Ligands 19%
23. Magnetic Resonance Imaging 6%
24. Maximum Tolerated Dose 43%
25. Mouse Mog protein 18%
26. Multiple Sclerosis 100%
27. myelin oligodendrocyte glycoprotein (35-55) 85%
28. Myelin Sheath 10%
29. Myelin-Oligodendrocyte Glycoprotein 39%
30. Negotiating 11%
31. Paralysis 16%
32. Peptide Fragments 23%
33. Peptides 76%
34. Pharmaceutical Preparations 57%
35. Plasmids 8%
36. Protein Isoforms 14%
37. Proteins 10%
38. Recombinant DNA 12%
39. Recombinant Proteins 17%
40. Safety 17%
41. Sclerosis 37%
42. T-Lymphocytes 75%
43. Technology 11%
44. Therapeutics 11%
45. Transgenic Mice 42%
46. White Matter 15%